DOI QR코드

DOI QR Code

서울 서남부지역 혈액투석 환자의 빈혈 및 칼슘-인 대사 현황

Prevalence of Anemia and Calcium-Phosphorus Abnormalities in Hemodialysis Patients in Southwestern Seoul

  • 이영기 (한림대학교 의과대학 내과학교실 및 신장연구소) ;
  • 김소윤 (연세대학교 의과대학 의료법윤리학교실) ;
  • 백수진 (이화여자대학교 생명의료법연구소) ;
  • 김성남 (김성남내과의원) ;
  • 강우헌 (삼성명인내과의원) ;
  • 강나리 (서울의료원 내과) ;
  • 김기원 (국립암센터 신장클리닉) ;
  • 전용덕 (국립중앙의료원 내과) ;
  • 손승환 (손승환내과의원) ;
  • 김대중 (성균관대학교 의과대학 삼성서울병원 신장내과)
  • Lee, Young-Ki (Department of Internal Medicine, Hallym Kidney institute, Hallym University College of Medicine) ;
  • Kim, So Yoon (Department of Medical Law and Ethics, Yonsei University College of Medicine) ;
  • Baek, Soo Jin (Ewha Institute for Biomedical Law and Ethics, Ewha Womans University) ;
  • Kim, Seong Nam (Seong Nam Kim Internal Medicine Clinic) ;
  • Kang, Woo Hun (Samsung Myungin Internal Medicine Clinic) ;
  • Kang, Na Ree (Department of Internal Medicine, Seoul Medical Center) ;
  • Kim, Kiwon (Nephrology Clinic, National Cancer Center) ;
  • Jeon, Yong Deok (Department of Internal Medicine, National Medical Center) ;
  • Son, Seung Hwan (Seung Hwan Son Internal Medicine Clinic) ;
  • Kim, Dae Joong (Division of Nephrology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 투고 : 2012.11.08
  • 심사 : 2013.01.17
  • 발행 : 2013.10.01

초록

목적: 혈액투석 환자와 인공신장실은 해마다 늘고 있으며 대한신장학회에서는 2009년부터 말기신부전 환자에 대한 의료서비스의 질 관리 및 건전한 인공신장실 운영을 위하여 인공신장실 인증시범사업을 시행하고 있다. 저자들은 인공신장실 인증제도 시범사업 결과를 분석하여 서울 서남부 혈액투석 환자들의 빈혈, 칼슘, 인 대사장애에 대한 관리 실태를 알아보고자 하였다. 방법: 인공신장실 인증제도 1차 시범사업에 참여한 25개 의료기관의 혈액투석 환자 1,524명에서 빈혈, 철저장능, 혈청 칼슘, 인 수치를 조사하였고, 철분 부족 환자에서 철분주사 투여율을 분석하였다. 또한 인증기관(12개)과 불인증기관(13개)에 따라 각 항목을 비교하였다. 결과: 대상 환자의 평균 혈색소 수치는 10.5 ${\pm}$ 1.5 g/dL였으며 혈색소 10 g/dL 이하인 빈혈 환자 비율은 27.4%이었고, 철 부족 환자는 25.2%였다. 그리고 철 부족 환자에서 철분주사의 투여율은 48.1%로 조사되었다. 평균 혈청 인 수치는 5.1 ${\pm}$ 1.9 mg/dL이었으며 혈청 칼슘-인 농도의 곱이 55 $mg^2/dL^2$ 미만인 환자 비율은 70.7%로 나타났다. 빈혈과 철저장능 충족률, 혈청 칼슘-인 농도는 인증기관과 불인증기관이 비슷하였으나 철 부족 환자에서 철분주사의 투여율은 인증기관(65.6%)이 불인증기관(30.9%)보다 더 높았다. 결론: 서울 서남부 혈액투석 환자들의 빈혈, 칼슘, 인 대사장애는 비교적 잘 관리되었으나 일부 기관에서는 좀 더 철저한 철분 관리가 필요하다. 우리나라 투석 환자의 빈혈, 칼슘-인 대사 이상 및 사망률에 대해 전향적으로 데이터를 추적하여 결론을 도출하려면 인증사업을 활성화할 필요가 있을 것으로 생각한다.

Background/Aims: The number of hemodialysis patients and dialysis centers is increasing each year, but there are no quality standards for facilities. Thus, the Korean Society of Nephrology carried out a pilot project regarding a hemodialysis center accreditation system. This study was aimed at surveying the prevalence of anemia and abnormalities of calcium or phosphorus metabolism in hemodialysis patients in southwestern Seoul. Methods: We investigated anemia, serum calcium, and phosphorus levels in 1,524 patients in 25 hemodialysis units. The rate of iron injections in patients with iron deficiency was also evaluated. Each item was compared between accredited (n = 12) and non-accredited centers (n = 13). Results: The mean hemoglobin in subjects was 10.5 ${\pm}$ 1.5 g/dL. The prevalences of anemia and iron deficiency were 27.4% and 25.2%, respectively. The rate of iron injection in patients with iron deficiency was 48.1%. The mean phosphorus level was 5.1 ${\pm}$ 1.9 mg/dL and the proportion of patients with Ca ${\times}$ P < 55 $mg^2/dL^2$ was 70.7%. The prevalence of anemia, iron deficiency, and Ca ${\times}$ P were similar between accredited and non-accredited centers. The rate of iron injection in iron deficiency was higher in accredited(65.6%) than non-accredited centers (30.9%). Conclusions: Management of anemia and levels of calcium or phosphorus were acceptable in hemodialysis patients in southwestern Seoul, although some facilities should make more efforts to improve iron deficiency. The availability of data from a hemodialysis center accreditation system allowed us a unique opportunity to further explore the relationships between anemia, abnormalities of mineral metabolism, and outcomes.

키워드

참고문헌

  1. Collins AJ, Li S, St Peter W, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001;12:2465-2473.
  2. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-590. https://doi.org/10.1056/NEJM199808273390903
  3. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15: 2208-2218. https://doi.org/10.1097/01.ASN.0000133041.27682.A2
  4. Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008;52: 519-530. https://doi.org/10.1053/j.ajkd.2008.03.020
  5. Collins AJ, Foley R, Herzog C, et al. Excerpts from the United States Renal Data System 2007 annual data report. Am J Kidney Dis 2008;51(1 Suppl 1):S1-320.
  6. Korean Society of Nephrology, ESRD Registry Committee. Current renal replacement therapy in Korea-Insan memorial dialysis registry 2010. Korean J Nephrol 2011;30(Suppl 2): S531-557.
  7. Lee YK, Kim SY. The accreditation system of renal dialysis unit. Korean J Nephrol 2010;29(Suppl 2):S588-593.
  8. KDOQI. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007;50:471-530. https://doi.org/10.1053/j.ajkd.2007.06.008
  9. KDOQI; National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006;47(5 Suppl 3):S11-145. https://doi.org/10.1053/j.ajkd.2006.03.010
  10. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(4 Suppl 3):S1-201.
  11. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKDMBD). Kidney Int Suppl 2009;(113):S1-130.
  12. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca${\times}$PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12: 2131-2138.

피인용 문헌

  1. Factors Associated with Quality Control of Hemodialysis Treatment vol.87, pp.4, 2013, https://doi.org/10.3904/kjm.2014.87.4.439